Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present a corporate overview at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for January 15, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The company will participate in a presentation and one-on-one investor meetings, and a webcast will be available.
Details
News Market Reaction – CRBP
On Jan 5, the day this news came out, CRBP closed 0.51% below the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference dates
- January 12–15, 2026
- 2026 Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 15, 2026
- Corbus corporate overview presentation
- Presentation time
- 8:15 a.m. PST / 11:15 a.m. EST
- Scheduled conference session
Historical Context
-
Phase 1a CRB-913 obesity data with early weight-loss signal and safety profile.
-
Announcement of upcoming Phase 1a CRB-913 data release and webcast details.
-
Q3 2025 results, CRB-701 efficacy data, financing update and runway into 2028.
-
Schedule of multiple late-2025 investor conferences with webcasts and meetings.
-
Dilutive public equity and pre-funded warrant offering of about $75M gross.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.
44th Annual J.P. Morgan Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: January 15, 2026
Presentation Time 8:15 a.m. PST/11:15am EST
Webcast Link: Click Here
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.